Phase 3Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
- Sponsor
- Alliance for Clinical Trials in Oncology (Academic or other)
- Enrollment
- 1,524 planned
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2+ Breast Cancer
- Interventions
- Trastuzumab (Herceptin); Pertuzumab; Echocardiography; Multigated Acquisition Scan; Mammography; Ultrasound; Magnetic Resonance Imaging; Biospecimen Collection; Questionnaire Administration
- Ages
- adults, older adults
- Registry
- NCT06876714
Full record on ClinicalTrials.gov
From the registry
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Primary outcomes
- Recurrence-free survival (RFS)
- Functional Assessment of Cancer Therapy-Breast (FACT-B) total score (Quality of life)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered